Maze Therapeutics (MAZE) Cash from Financing Activities (2024 - 2026)

Maze Therapeutics' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $42.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 66.75% year-over-year to $42.4 million; the TTM figure through Mar 2026 stood at $190.3 million (down 2.72% YoY), while the FY2025 annual figure was $275.3 million, up 196.55% from the prior year.
• Cash from Financing Activities came in at $42.4 million for Q1 2026 at Maze Therapeutics, up from $3.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $143.8 million in Q3 2025 to a low of -$2.2 million in Q3 2024.
• A 3-year average of $45.6 million and a median of $24.6 million in 2024 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 6786.37% in 2025 and fell as far as 94.89% in 2025.
• Maze Therapeutics' Cash from Financing Activities stood at $70.3 million in 2024, then tumbled by 94.89% to $3.6 million in 2025, then soared by 1079.86% to $42.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $42.4 million, $3.6 million, and $143.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison